 |
|
Effect of Hepatitis A Vaccination Programs
Pierre Van Damme, MD, PhD;
Koen Van Herck, MD
JAMA. 2005;294:246-248.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
When new vaccines are developed, the epidemiology and pathology of vaccine-preventable infectious diseases are revisited and rewritten. This was true with hepatitis A vaccines more than 10 years ago. Hepatitis A epidemiology shows that an increasing part of the adolescent and adult population in industrialized countries is becoming susceptible to hepatitis A virus infection, as infection in childhood decreases.1-3
Currently, 5 vaccines against hepatitis A are available. Two inactivated hepatitis A vaccines have been approved for use in most parts of the world, including the United States.4-5 These vaccines are licensed for children aged 1 year or older, except in the United States where the vaccine is licensed for children aged 2 years or older. Two other inactivated vaccines are licensed in Europe, Canada, and in other countries around the world.6-7 Another live, attenuated hepatitis A vaccine is currently used in . . . [Full Text of this Article]
Author Affiliations: Centre for the Evaluation of Vaccination, WHO Collaborating Centre for the Prevention and Control of Viral Hepatitis, Department of Epidemiology and Social Medicine, University of Antwerp, Belgium.
RELATED ARTICLES
Incidence of Hepatitis A in the United States in the Era of Vaccination
Annemarie Wasley, Taraz Samandari, and Beth P. Bell
JAMA. 2005;294(2):194-201.
ABSTRACT
| FULL TEXT
Incidence of Hepatitis A in Israel Following Universal Immunization of Toddlers
Ron Dagan, Alex Leventhal, Emilia Anis, Paul Slater, Yaffa Ashur, and Daniel Shouval
JAMA. 2005;294(2):202-210.
ABSTRACT
| FULL TEXT
|
